Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

"Investigating the rebound effects of seasonal malaria chemoprevention (SMC) in Mali"

Award Number: R01AI169517
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/05/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2027

Group Awards By:

View Award Description

"Investigating the rebound effects of seasonal malaria chemoprevention (SMC) in Mali" - Summary Seasonal Malaria Chemoprevention (SMC) has been recommended by WHO for malaria endemic countries in sub-Saharan Africa with strong seasonal malaria transmission since 2012. The intervention consists of the administration of full treatment doses of Sulfadoxine-Pyrimethamine (SP) plus Amodiaquine to children less than 5 years of age every 4 weeks during the malaria transmission season for 3 to 4 rounds per year. Since 2016, Mali has implemented the strategy countrywide. While significant decreases in malaria cases among the target age group was observed, increasing trends in malaria among children 5 years and above is also reported in the many settings where SMC is being implemented. The proposed study considers previous studies and pilot data showing that approximately out of every eight children (12.5%) have historically received either no doses or a single dose out of a the required four doses for the treatment regimen. This study seeks to enroll a large cohort of children to permit a large-scale comparison between children previously compliant to SMC with a valid control group (children not previously compliant to SMC) to elucidate the effects of phasing out of the SMC program due to age ineligibility. The primary objective of this R01 proposal is to investigate the withdrawal effects of SMC due to age eligibility requirements through the following three specific aims: 1) Determine malaria rebound occurrence following SMC enrollment including its association with severe malaria and anemia; 2) Assess changes in the age-specific P. falciparum prevalence, sexual and asexual parasites, and multiplicity of infection following SMC deployment; and 3) Assess the change in immune response to malaria antigens during and following SMC eligibility and the relationship with disease. The study will provide valuable information on the impact of SMC stoppage at five years of age which can significant contribute improving monitoring malaria outcomes in other low- and middle-income countries overall.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $130,758 )
2025	2025	UNIVERSITE DES SCIENCES, DES TECHNIQUES ET DES TECHNOLOGIES DE BAMAKO (USTTB)	HAMDALLAYE ACI 2000	BAMAKO				MLI	Allergy and Infectious Diseases Research	000	4	9/9/2025	NON-COMPETING CONTINUATION	$130,758
														Subtotal = $130,758

Issue Date FY: 2024 ( Subtotal = $130,918 )
2024	2024	UNIVERSITE DES SCIENCES, DES TECHNIQUES ET DES TECHNOLOGIES DE BAMAKO (USTTB)	HAMDALLAYE ACI 2000	BAMAKO				MLI	Allergy and Infectious Diseases Research	000	3	8/22/2024	NON-COMPETING CONTINUATION	$130,918
														Subtotal = $130,918

Issue Date FY: 2023 ( Subtotal = $130,918 )
2023	2023	UNIVERSITE DES SCIENCES, DES TECHNIQUES ET DES TECHNOLOGIES DE BAMAKO USTTB	HAMDALLAYE ACI 2000	BAMAKO				MLI	Allergy and Infectious Diseases Research	000	2	8/3/2023	NON-COMPETING CONTINUATION	$130,918
														Subtotal = $130,918

Issue Date FY: 2022 ( Subtotal = $133,320 )
2022	2022	UNIVERSITE DES SCIENCES, DES TECHNIQUES ET DES TECHNOLOGIES DE BAMAKO USTTB	HAMDALLAYE ACI 2000	BAMAKO				MLI	Allergy and Infectious Diseases Research	000	1	9/5/2022	NEW	$133,320
														Subtotal = $133,320

Grand Total All Awards = $525,914

Top

All Categories

About

Search

Reports

Data Submission

Award Information

"Investigating the rebound effects of seasonal malaria chemoprevention (SMC) in Mali"

Award Number: R01AI169517

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/05/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer